@article{e290c09dc9704d8aa1e622a8a3655a57,
title = "Using Network Parcels and Resting-State Networks to Estimate Correlates of Mood Disorder and Related Research Domain Criteria Constructs of Reward Responsiveness and Inhibitory Control",
abstract = "Background: Resting-state graph-based network edges can be powerful tools for identification of mood disorders. We address whether these edges can be integrated with Research Domain Criteria (RDoC) constructs for accurate identification of mood disorder–related markers, while minimizing active symptoms of disease. Methods: We compared 132 individuals with currently remitted or euthymic mood disorder with 65 healthy comparison participants, ages 18–30 years. Subsets of smaller brain parcels, combined into three prominent networks and one network of parcels overlapping across these networks, were used to compare edge differences between groups. Consistent with the RDoC framework, we evaluated individual differences with performance measure regressors of inhibitory control and reward responsivity. Within an omnibus regression model, we predicted edges related to diagnostic group membership, performance within both RDoC domains, and relevant interactions. Results: There were several edges of mood disorder group, predominantly of greater connectivity across networks, different than those related to individual differences in inhibitory control and reward responsivity. Edges related to diagnosis and inhibitory control did not align well with prior literature, whereas edges in relation to reward responsivity constructs showed greater alignment with prior literature. Those edges in interaction between RDoC constructs and diagnosis showed a divergence for inhibitory control (negative interactions in default mode) relative to reward (positive interactions with salience and emotion network). Conclusions: In conclusion, there is evidence that prior simple network models of mood disorders are currently of insufficient biological or diagnostic clarity or that parcel-based edges may be insufficiently sensitive for these purposes.",
keywords = "Depression, Imaging, Inhibitory control, Mood disorders, Resting-state, Reward",
author = "Langenecker, {Scott A.} and {Westlund Schreiner}, Mindy and Thomas, {Leah R.} and Bessette, {Katie L.} and DelDonno, {Sophia R.} and Jenkins, {Lisanne M.} and Easter, {Rebecca E.} and Stange, {Jonathan P.} and Pocius, {Stephanie L.} and Alina Dillahunt and Love, {Tiffany M.} and Phan, {K. Luan} and Vincent Koppelmans and Martin Paulus and Lindquist, {Martin A.} and Brian Caffo and Mickey, {Brian J.} and Welsh, {Robert C.}",
note = "Funding Information: SAL reports financial disclosures from EPI-Q, Otsuka Pharmaceutical Development and Commercialization, Inc, and Secondary Triad, Inc, all of which are unrelated to the present work. SAL is supported by National Institute of Mental Health grants (Grant Nos. MH116080, MH112705, MH120660, and MH120168), all unrelated to this work. MP is an adviser to Spring Care, Inc, a behavioral health startup, and he has received royalties for an article about methamphetamine in UpToDate. MP is supported by National Institute of Mental Health (Grant No. R01 MH101453), National Institute on Drug Abuse (Grant No. U01 DA041089), and National Institute of General Medical Sciences (Grant No. P20GM121312) unrelated to this work. BJM reports having received research funding from LivaNova and Novartis and consulting fees from Alkermes; he is an unpaid advisory board member for Futramed. All other authors report no biomedical financial interests or potential conflicts of interest. Funding Information: Support for the work was provided by Grant Nos. MH091811 and MH101487 (to SAL), including support for the effort of KLB, SRD, LMJ, REE, JPS, SLP, and KLP. We thank the patients and participants who were involved in the study and the research assistants and functional magnetic resonance imaging technicians who were involved in data collection. SAL reports financial disclosures from EPI-Q, Otsuka Pharmaceutical Development and Commercialization, Inc, and Secondary Triad, Inc, all of which are unrelated to the present work. SAL is supported by National Institute of Mental Health grants (Grant Nos. MH116080, MH112705, MH120660, and MH120168), all unrelated to this work. MP is an adviser to Spring Care, Inc, a behavioral health startup, and he has received royalties for an article about methamphetamine in UpToDate. MP is supported by National Institute of Mental Health (Grant No. R01 MH101453), National Institute on Drug Abuse (Grant No. U01 DA041089), and National Institute of General Medical Sciences (Grant No. P20GM121312) unrelated to this work. BJM reports having received research funding from LivaNova and Novartis and consulting fees from Alkermes; he is an unpaid advisory board member for Futramed. All other authors report no biomedical financial interests or potential conflicts of interest. Publisher Copyright: {\textcopyright} 2021 Society of Biological Psychiatry",
year = "2022",
month = jan,
doi = "10.1016/j.bpsc.2021.06.014",
language = "English (US)",
volume = "7",
pages = "76--84",
journal = "Biological Psychiatry: Cognitive Neuroscience and Neuroimaging",
issn = "2451-9022",
publisher = "Elsevier Inc.",
number = "1",
}